Molecular diagnostics of non-small cell lung cancer. New markers and technologies

被引：0
|
作者：
Warth, A. [1 ,3 ]
Endris, V. [1 ]
Kriegsmann, M. [1 ]
Stenzinger, A. [1 ]
Penzel, R. [1 ]
Pfarr, N. [1 ]
Weichert, W. [1 ,2 ]
机构：
[1] Univ Klinikum Heidelberg, Inst Pathol, D-69120 Heidelberg, Germany
[2] NCT, Heidelberg, Germany
[3] Mitglied Deutsch Zentrums Lungenforsch DZL TLRC, Translat Lungenforschungszentrum, Heidelberg, Germany
来源：
PATHOLOGE | 2015年 / 36卷 / 02期
关键词：
Lung cancer; Molecular diagnostics; Sequential testing; Massively parallel sequencing; Immunomodulatory drugs; CIRCULATING TUMOR DNA; INTERNATIONAL ASSOCIATION; GENE REARRANGEMENT; MASS-SPECTROMETRY; PLASMA DNA; PHASE-III; ERCC1; ADENOCARCINOMA; CHEMOTHERAPY; CRIZOTINIB;
D O I：
10.1007/s00292-015-0004-4
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.
引用
收藏
页码：154 / 163
页数：10
相关论文
共 50 条
  • [1] Non-small cell lung cancer. New biomarkers for diagnostics and therapy
    Kayser, G.
    [J]. PATHOLOGE, 2015, 36 : 189 - 193
  • [2] Immunological markers of outcome of non-small cell lung cancer.
    Potter, DA
    Amin, C
    Mohiuddin, A
    Badve, S
    Davidson, D
    Kesler, K
    Hanna, N
    Edenberg, H
    Einhorn, L
    Mitra, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 678S - 678S
  • [3] Pathophysiology and molecular diagnostics in non-small cell lung cancer
    Heukamp, C.
    Wolf, J.
    Buettner, R.
    [J]. ONKOLOGE, 2011, 17 (08): : 670 - +
  • [4] Molecular diagnostics of non-small cell lung cancer: New markers and technologies [Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien]
    Warth A.
    Endris V.
    Kriegsmann M.
    Stenzinger A.
    Penzel R.
    Pfarr N.
    Weichert W.
    [J]. Der Pathologe, 2015, 36 (2): : 154 - 163
  • [5] Predictive molecular markers in non-small cell lung cancer
    Rosell, R
    Tarón, M
    O'Brate, A
    [J]. CURRENT OPINION IN ONCOLOGY, 2001, 13 (02) : 101 - 109
  • [6] Prognostic molecular markers in non-small cell lung cancer
    Niklinski, J
    Niklinska, W
    Laudanski, J
    Chyczewska, E
    Chyczewski, L
    [J]. LUNG CANCER, 2001, 34 : S53 - S58
  • [7] MOLECULAR MARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Heigener, D.
    [J]. ANTICANCER RESEARCH, 2011, 31 (05) : 1979 - 1979
  • [8] Prognostic significance of immunohistochemical markers in non-small cell lung cancer.
    Renouf, D.
    Wood-Baker, R.
    Ionescu, D.
    Leung, S.
    Massoudi, H.
    Gilks, B.
    Laskin, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 416S - 416S
  • [9] Cytopathology and molecular diagnostics of non-small cell lung cancer (NSCLC)
    Fassunke, Jana
    Engels, Marianne
    Meemboor, Sonja
    Buettner, Reinhard
    [J]. INNERE MEDIZIN, 2022, 63 (07): : 694 - 699
  • [10] Advanced non-small cell lung cancer.
    Edelman M.J.
    Khanwani S.L.
    [J]. Current Treatment Options in Oncology, 2001, 2 (1) : 51 - 62
12345